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Abstract: Fullerenols are nanosized water-soluble polyhydroxylated derivatives of fullerenes,
a specific allotropic form of carbon, bioactive compounds, and perspective basis for drug development.
Our paper analyzes the antioxidant activity and toxicity of a series of fullerenols with different
number of oxygen substituents. Two groups of fullerenols were under investigation: (1) C60Oy(OH)x,
C60,70Oy(OH)x, where x+y = 24–28 and (2) C60,70Oy(OH)x, Fe0,5C60Oy(OH)x, Gd@C82Oy(OH)x,
where x+y = 40–42. Bioluminescent cellular and enzymatic assays (luminous marine bacteria and
their enzymatic reactions, respectively) were applied to monitor toxicity in the model fullerenol
solutions and bioluminescence was applied as a signaling physiological parameter. The inhibiting
concentrations of the fullerenols were determined, revealing the fullerenols’ toxic effects. Antioxidant
fullerenol’ ability was studied in solutions of model oxidizer, 1,4-benzoquinone, and detoxification
coefficients of general and oxidative types (DGT and DOxT) were calculated. All fullerenols produced
toxic effect at high concentrations (>0.01 g L−1), while their antioxidant activity was demonstrated at
low and ultralow concentrations (<0.001 g L−1). Quantitative toxic and antioxidant characteristics
of the fullerenols (effective concentrations, concentration ranges, DGT, and DOxT) were found to
depend on the number of oxygen substituents. Lower toxicity and higher antioxidant activity were
determined in solutions of fullerenols with fewer oxygen substituents (x+y = 24–28). The differences
in fullerenol properties were attributed to their catalytic activity due to reversible electron acceptance,
radical trapping, and balance of reactive oxygen species in aqueous solutions. The results provide
pharmaceutical sciences with a basis for selection of carbon nanoparticles with appropriate toxic and
antioxidant characteristics. Based on the results, we recommend, to reduce the toxicity of prospective
endohedral gadolinium-fullerenol preparations Gd@C82Oy(OH)x, decreasing the number of oxygen
groups to x+y = 24–28. The potential of bioluminescence methods to compare toxic and antioxidant
characteristics of carbon nanostructures were demonstrated.
Keywords: bioactive compound; fullerenol; antioxidant activity; toxicity; reactive oxygen species;
bioluminescence bioassay
1. Introduction
Carbon nano-objects are of great interest for different fields of medicine, pharmacology,
and biotechnology due to their specific biological activity [1–3]. It is known that high-dose exposures
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to bioactive compounds can inhibit physiological functions of multiple organisms and, hence, produce
toxic effects, while low-dose exposures can activate the physiological functions due to optimization of
complex metabolic processes [4].
Fullerenols (F) are known to be rigid nanosized carbon particles, and are water-soluble
polyhydroxylated derivatives of fullerenes. Scheme 1 presents the hypothetical structure of F with 60
carbon atoms as an example.
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Scheme 1. Hypothetical structure of fullerenol C60.
Similar to fullerenes, fullerenols are electron-deficient structures and this property makes them
efficient catalyzers in biochemical reactions, as well as in prospective me ical drugs. Fullerenols are
amphiphilic structures: “hydroxyl groups provide them with aqueous solubility, while the fragments
of fullerene skeleton—wit affinity to hydro hobic enzy atic fragments and lipid structures of
cellular membranes” [1,2]. Amphiphilic properties an antiradical activity provide a wide range
of fullerenols’ biological effects: from neutralization of free radicals [5] to cell protection and drug
transportation [1,5–7]. Fullerenols can be used in radiobiology, chemotherapy, and neurology [5,6],
ensuring an important alternative to conventional pharmaceuticals. The antioxidant properties endow
fullerenols with the ability to neutralize reactive oxygen and nitrogen species [8–12], and to function as
radioprotectors [10], antitumor [13], or neurological [5,10–12] drugs.
Structural properties influence the biological activity of fullerenols. Hydroxyl substituents distort
the pi-electron system conjugation of the fullerene skeleton, change the electron-acceptor ability of the
nanoparticles, and, hence, can affect their catalytic activity. This can result in different toxicity and
antioxidant activity of fullerenols with different number of hydroxyl substituents.
Biological activity of C60-fullerenols with different number of hydroxyl groups have been studied
over the last decades [5–9]. Toxic and antioxidant effects of fullerenols were revealed. However,
different biological test objects did not provide a comparability of the fullerenol biological activity.
Comparable conditions were provided by Eropkin and co-authors [14]. They studied the biological
activity of a series of fullerenols, C60(OH)12–14, C60(OH)18–24, and C60(OH)30–38. It was found that
C60(OH)12–14 was insoluble in water and did not show biological activity, while C60(OH)18–24 was
soluble and sho ed maximum antiviral and protective properties. The nitric oxide-scavenging
and protective activity of C60(OH)18–24 was demonstrated in [5,8]. However, in spite of extensive
studies of fullerenol biological activity, dependencies of their toxic and antioxidant characteristics on
concentrations were not revealed and compared.
Hydration of C60-fullerenol with different number of hydroxyl groups (from 8 to 44) was
theoretically studied in [15]. It was proved that hydration of C60(OH)44 was less effective despite the
large number of hydroxyl groups. The authors concluded that the involvement of >36 hydroxyl groups
to the fullerenol structure resulted in effective intramolecular interactions of OH-groups, conflicting
with the hydrogen bonds with the solvent.
Since an increase of a number of hydroxyl substituents reduces the available pi-electron system
conjugation, it can reduce fullerenols’ ability of reversible radical trapping [14]. This might be a reason
for the variation in content of reactive oxygen species (ROS) in aerated aqueous solutions, with effects
on the following biological structures: cells, enzymes, low-molecular components, etc.
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It is known that ROS groups include a number of free oxygen radicals or radical precursors,
such as semiquinones, superoxide anion-radical (•O2−), hydroxyl (•OH) and peroxide (HOO•) radicals,
hydrogen peroxide (H2O2), peroxide anion (HOO−), singlet oxygen (1O2) [16], hypochloric acid (HOCl),
peroxynitrite radical (ONOO-), and others. They are formed in cells as natural products of oxygen
metabolism, their content is labile, and they can initiate formation of additional radicals. ROS play
a role as mediators of important intracellular signaling pathways [17], thereby regulating cellular
processes (respiration, division, etc.), inducing the immune system, mobilizing ion transport systems,
and triggering programmed cell death (apoptosis) [18].
Fullerenols’ catalytic activity is due to electron donation/acceptance and oxygen radical scavenging.
For example, the process of O2•−- neutralization can be presented as follows:
2O•−2 + 2H2O
F→H2O2 + 2OH− + O2
where F plays the role of a catalyzer. A detailed description of possible mechanisms of oxygen radicals’
neutralization is presented in [11].
As the ROS impact on living organisms is evident [19–27], a study of ROS content in fullerenol’
solutions can elucidate the mechanism of fullerenol’ biological effects.
Our paper used the physico-chemical approach to study the properties of bioactive compounds.
This approach is based on the “structure-function” relations and allows for predicting the toxic and
antioxidant properties of fullerenols. The relations can help in further applied studies, from synthesis to
medical adaptation. Additionally, the relations can help to minimize further routine experiments with
organs and whole organisms, which are usually time-consuming, expensive, and less reproducible.
The physico-chemical approach assumes an application of simple biological assays as models.
We applied two types of bioassays of different levels of organization—cellular and enzymatic.
Both bioassays used luminescence intensity as a test parameter. Luminescent registration provides high
rates, low costs, and convenience of the bioassay procedures; it ensures simultaneous multiple analyses
and, hence, proper statistical processing and reliability for the results of biomedical investigations.
Cellular bioassay is based on luminous marine bacterium. This bioassay is classic and has been
widely used for more than five decades [28–33]. Enzymatic bioluminescence assay progressed from
early 90s [29,34–36]. Solid immobilized bacterial and enzymatic preparations are developed now as a
basis for bioluminescent biosensors [34,37–40]. The bacterial and enzymatic bioassays are tools for
investigation of the toxic mechanisms at the cellular and molecular levels, respectively. Classification
of the toxic effects was suggested first in [41] and developed later in [42–45]. It describes the (1)
physicochemical, (2) chemical, and (3) biochemical basis for the toxic effects in the bioluminescence
assay systems.
Antioxidant properties of bioactive compounds provided a new perspective for biosensor
applications [46,47]. The bioassay systems, based on the luminous bacterium or its enzymatic reactions,
are proper candidates for this application. Both assays can evaluate a general toxicity in the test
samples under conditions of the oxidative stress. Additionally, the enzymatic bioassay is specific
to oxidizers [45] and can be applied to monitor the oxidative toxicity in the solutions. This type of
toxicity is attributed to the redox properties of the toxic compounds only, while the other toxicity type,
general toxicity, integrates all interactions of toxic compounds with the bioluminescent assay system:
redox reactions, polar and non-polar interactions, etc. Previously [48,49], we evaluated the general and
oxidative toxicities in solutions of inorganic and organic oxidizers (polyvalent metals and quinones)
using the bioluminescent enzymatic assay system. Changes in general toxicity and oxidative toxicity
under exposure to humic substances (bioactive compounds of natural origination, products of organics
decomposition in soils) were studied in [50–52]. The bioluminescence technique for evaluating the
antioxidant activity of bioactive compounds was described in [53–55]. Antioxidant properties of two
fullerenols were studied for the first time and compared using bioluminescence enzymatic technique
in [53].
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The current study develops a fundamental basis for fullerenol medical application. We review,
analyze, and compare our new and previous experimental results, obtained under comparable
conditions. Our paper analyzes antioxidant activity and toxicity of a series of fullerenols with different
numbers of oxygen substituents. Chemical formulas of the fullerenols and their short abbreviations
are presented in Table 1. The fullerenols were attributed to two clusters involving either 24–28 or 40–42
oxygen substituents (F1, F2 or F3, F4, F5, respectively, Table 1). Enzyme-based and cellular-based
luminescent bioassays were applied to evaluate toxicity and antioxidant properties of the fullerenols.
Ranges of toxic and antioxidant concentrations of fullerenols were of particular attention. Quantitative
antioxidant characteristics (detoxification coefficients) are presented in a wide range of fullerenol
concentrations. Possible antioxidant mechanisms and the role of ROS in the effects of the fullerenols are
discussed. Toxic effect of a perspective endohedral metal-fullerenol with gadolinium atom involved
(F5, Table 1) is evaluated. A recommendation is provided for the synthesis of new low-toxic endohedral
gadolinium-fullerenol preparation.
Table 1. Fullerenol’ chemical formulas and short abbreviations.
Chemical Formula x+y Abbreviation
C60Oy(OH)x 24–28 F1
C60,70Oy(OH)x 24–28 F2
C60,70Oy(OH)x 40–42 F3
Fe0,5C60Oy(OH)x 40–42 F4
Gd@C82Oy(OH)x 40–42 F5
2. Results and Discussion
2.1. Toxicity and Antioxidant Activity of Fullerenols via Bioluminescent Assays
2.1.1. Fullerenol Toxicity
We examined the toxicity factor of fullerenols with different number of oxygen groups using cellular
and enzymatic bioluminescence assays. Suppression of bioluminescence intensity was considered to be
evidence of fullerenol toxic effect. This suppression is concerned with the inhibition of membrane and
intracellular processes (for bacterial cells), or chemical and biochemical reactions (for enzyme system).
Dependencies of relative bioluminescence intensities IrelF (Equation (1)) on the concentration of
the fullerenols were obtained. Examples of these dependencies are presented in Figures 1 and 2.
Fullerenols F2 and F3 were chosen as nanostructures with similar carbon carcasses, but different
number of oxygen substituents. It is seen that F2 and F3 suppressed bioluminescence of the cellular
assay at concentrations >0.002 g·L−1 and >0.001 g·L−1 (Figure 1), and suppressed bioluminescence of
the enzymatic assay at concentrations >0.010 g·L−1 and >0.003 g·L−1 (Figure 2), respectively. The results
demonstrate the higher toxicity of F3, i.e., fullerenol with more oxygen substituents.
Fullerenol’ effective concentrations EC50 were determined and are presented in Table 2. It is
evident from this Table that F1 and F2 (i.e., fullerenols with lower oxygen numbers) were characterized
by higher EC50 values and, hence, produced lower toxicity effects, as compared to fullerenols F3, F4,
and F5. The EC50 value of F4 in the bacterial assay (0.021 g L−1, Table 2) was an exception. Probably,
iron atoms, involved in the fullerenol preparation, specifically affected the metabolism of the bacterial
cells, according to their microelement properties.
Toxicity of the new endohedral metal-fullerenol F5 (gadolinium atom inside the fullerenol carbon
carcass) was studied using the enzyme-based bioassay, Table 2.
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toxicity of gadolinium-based chemotherapeutic drugs limits their clinical application. They are 
known to lead to severe skin and systemic diseases, renal dysfunction [57], and intracranial 
deposition of gadolinium [58]. The problem of toxicity of gadolinium preparations might be solved 
by involvement of gadolinium into the fullerenol carcass. An endohedral gadolinium-fullerenol 
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(F5, EC50 = 0.018 g L-1, Table 2), and it is desirable to reduce this toxicity. Since the results of the 
current study predicted lower toxicity of the preparations with fewer oxygen substituents, we can 
recommend synthesis of endohedral gadolinium-fullerenol preparations with fewer oxygen groups: 
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Figure 2. Bioluminescence intensity, Irel, at different concentrations of fullerenols F2 and F3 for the
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Table 2. Values of effective concentrations EC50 of fullerenols F1–F5 and concentration range (CR) of
F1–F5 for decreasing bioluminescent intensity less than 10% for both enzymatic and cellular assays.
Fullerenols
Cellular Assay Enzymatic Assay
Fullerenol Concentration (g L−1)
EC50 CR EC50 CR
F1 0.031 <0.010 0.092 <0.010
F2 0.008 <0.002 0.021 <0.010
F3 0.003 <0.001 0.007 <0.003
F4 0.021 <0.012 0.007 <0.001
F5 - - 0.018 <0.005
It is known that gadolinium-based preparations have potential in magnetic resonance imaging and
cancer research due to gadolinium’ unique paramagnetic properties [56]. However, the high toxicity of
gadolinium-based chemotherapeutic drugs limits their clinical application. They are known to lead to
severe skin and systemic diseases, renal dysfunction [57], and intracranial deposition of gadolinium [58].
The problem of toxicity of gadolinium preparations might be solved by involvement of gadolinium into
the fullerenol carcass. An endohedral gadolinium-fullerenol preparation Gd@C82Oy(OH)x where x+y
= 40–42, was synthesized as described in Section 3 (Materials and Methods). However, our preliminary
study demonstrated a moderate toxicity of this compound (F5, EC50 = 0.018 g L−1, Table 2), and it
is desirable to reduce this t xicity. Since the results of the current study predicted lower toxicity
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of the preparations with fewer oxygen substituents, we can recommend synthesis of endohedral
gadolinium-fullerenol preparations with fewer oxygen groups: x+y = 24–28 or lower, as a development
of these investigations. Bioluminescence toxicological monitoring can provide a prompt toxicity
evaluation of the newly synthesized gadolinium preparations at cellular and biochemical levels
(bacteria- and enzyme-based bioassays, respectively).
2.1.2. Fullerenol Antioxidant Activity
To compare the antioxidant activity of fullerenols, we chose a range of fullerenol concentrations
providing the absence of the fullerenol inhibiting effect. These concentration ranges (CR) are presented
in Table 2 for both cellular and enzymatic assays.
The antioxidant ability of fullerenols was studied using cell-based and enzyme-based assays
(luminous marine bacteria and their enzymatic reactions, respectively). The bioassays were applied
to monitor toxicity changes in solutions of the model oxidizer 1,4-benzoquinone under additions of
the fullerenols and bioluminescence was applied as a signaling physiological parameter. Changes in
toxicities of the general or oxidative type (GT or OxT, respectively) were evaluated, and detoxification
coefficients DGT or DOxT were calculated. Values of DGT > 1 and DOxT > 1 revealed a toxicity decrease
under the exposure to fullerenols, i.e., detoxification of solutions of the oxidizer.
Change in General Toxicity (GT) of Oxidizer Solutions Under Exposure to Fullerenols
Bioluminescence intensity in the cellular and enzymatic systems was measured in solutions of the
model oxidizer, 1,4-benzoquinone (at EC50), in the absence and presence of fullerenols. Concentrations
of the fullerenols varied in a wide range as shown in Figure 3; Figure 4 for bacterial and enzymatic assays,
respectively. Detoxification coefficients DGT were calculated according to Equation (2). The results are
presented in Figures 3 and 4, with F2 and F3 taken as examples. As discussed before [50], the difference
in the responses of cells and enzyme reactions can be attributed to the active role of the bioassay
systems in the detoxification processes. Antioxidant activity of low-concentration fullerenol solutions
was discussed previously [54] in terms of the hormesis phenomenon [4].
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Figure 3. Detoxification coefficients DG s. concentration of full renols F2 and F3 in solutions of
1,4-benzoquinone (2.5·10−7 M) ll lar a say.
Cellular ass y (Figure 3) showed that the oxidizer’ solutions were detoxified (DGT > 1) in the
concentration ra ges of 10−19–10−3 and 10−15−4 × 10−4 g L−1 for F2 and F3, respectively. Max mal
valu s f DGT were about 1.8 and 1.3, respectively.
Enzyme-based a says showed lower values of DGT, when compared with the cell-based assay.
Figure 4 demonstrates the detoxifying effect of F2 and F3 in 1,4-benzoquinone solutions (DGT > 1) in
the concentration ranges of 10−19–10−3 and 10−20−10−10 g L−1, respectively. Maximal values of DGT
were about 1.5 and 1.3, respectively.
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Change in Oxidative Toxicity (OxT) of Oxidizer Solutions Under Exposure to Fullerenols
Bioluminescence kinetics of the enzymatic system was studied in solutions of the model organic
oxidizer, 1,4-benzoquinone. Induction periods were measured in the absence and presence of fullerenols,
(T0.5)Ox and (T0.5)Ox+F, respectively. Detoxification coefficients DOxT were calculated ac ording to
Equation (3).
i r str t s t depen e ce of DOxT fullerenol concentrations. t ifi ti
c ffici ts xT in the solutions of organic oxidizer, ,4- e zoq inone, re c e . f r r
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The maximal values of DOxT of fullerenols F1, F2, F3, and F4 are presented in Table 4. Similar
to DGT (Table 3), the DOxT values of F1 and F2 were higher than these of F3 and F4, revealing higher
antioxidant ability of fullerenols with lower oxygen numbers.
Table 4. Maximal values of DOxT of fullerenols (F1–F4) in model solutions of organic oxidizer
(1,4-benzoquinone) for the enzymatic assay.
Fullerenols Maximal Value of DOxT
F1 2.0
F2 1.9
F3 1.0
F4 1.3
It should be noted that Figures 3–5 did not demonstrate monotonic linear dependencies of the
detoxification coefficients on fullerenol concentrations. The absence of such dependence is in accordance
with hormesis toxicological model for low-concentration solutions of bioactive compounds [4].
2.2. ROS Content in Fullerenol Solutions—Luminol Chemiluminescence Assay
We supposed that ROS content was directly related with oxidative toxicity (OxT) of the solutions.
Additionally, ROS contributed to general toxicity (GT) in a more complex way. Similar to excess of ROS,
the lack of ROS can suppress bioluminescence of the enzymatic system since the peroxide compounds
are involved in the bioluminescence reactions as intermediates [44]. Similar effects can take place in
other (non-bioluminescence) redox enzymatic reactions in cells.
We used the luminol chemiluminescence method to compare the content of ROS in the solutions
of fullerenols F1, F2, F3, and F4. Dependencies of ROS content on fullerenol concentrations were
studied. Fullerenols F2 and F3 were chosen as examples for presentation in Figure 6.
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Table 5 presents the fullerenol effective concentrations, which reduced ROS content by 50%, EC50.
The Table shows that F1 and F2 suppressed ROS less effectively than F3 and F4 (values of EC50 were
0.179 and 0.124 g L−1 as compared to 0.056 and 0.105 g L−1, r spectively).
Table 5. Values of EC50 of fullerenols in chemiluminescence assay.
Fullerenols EC50, g L−1
F1 0.179
F2 0.124
F3 0.056
F4 0.105
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Inhibition and activation of bacterial bioluminescence intensity by ROS were reported previously
for bacterial and enzymatic assays [59,60] where hydrogen peroxide was applied by the authors as a
representative of ROS.
Correlations between characteristics of chemiluminescence and bioluminescence assays (Tables 2
and 5, Tables 3 and 4, respectively) were studied to confirm involvement of ROS in toxic and antioxidant
effects of fullerenols F1–F4. Values of EC50, DGT, and DOxT were used to calculate correlation coefficients.
The correlation coefficient between EC50 values in the chemiluminescence assay (Table 5) and the
bioluminescence cellular assay (Table 2) was determined to be 0.88, while the correlation coefficient
between the chemiluminescence assay (Table 5) and the bioluminescence enzymatic assay (Table 2) was
0.83. Hence, both cells and enzymes demonstrated correlations between bioluminescence intensity and
ROS content. These results supported the hypothesis that ROS involvement in the bioluminescence
inhibition by the fullerenols, resulted in toxic effects of these compounds in high-concentration solutions.
The correlation coefficients between EC50 values in the chemiluminescence assay (Table 5) and
detoxification coefficients DGT and DOxT in the enzyme-based assay system (Tables 3 and 4) were
0.83 and 0.91, respectively. These results supported the suggestion of the involvement of ROS on the
antioxidant effect of fullerenols in the enzyme process. This effect took place under low concentrations
of fullerenols. The correlation coefficient between the EC50 values in the chemiluminescence assay
(Table 5) and the values of DGT obtained using the bioluminescence cellular assay (Table 3) was 0.13.
This value does not demonstrate a dependency on the ROS content, probably due to the complicated
structure of the cellular assay (as compared to the enzymatic one).
Our results showed that toxicity of fullerenols in high-concentration solutions might be related to
their extra ability to neutralize oxygen radicals. Fullerenols with higher number of oxygen substituents
(F3 and F4) suppressed ROS more effectively, producing more toxic effects on cellular and enzymatic
systems. The antioxidant activity of fullerenols in the low-concentration solutions was probably
related to their ability to regulate ROS content reversibly; fullerenols with lower number of hydroxyl
substituents (F1 and F2) were characterized by higher antioxidant activity. The results might predict
a higher antioxidant activity of non-substituted fullerenes, i.e., carbon nanostructures with holistic
pi-system apportioned evenly over the spherical macromolecule. Additional experiments under similar
conditions should be performed to confirm this suggestion. Previously [61–64], the biological activity
of hydrated C60 fullerene was studied and its activity was attributed to specific structure of hydrated
shell of the fullerene.
3. Materials and Methods
3.1. Preparations of Fullerenols
F1 and F2 were produced by fullerene hydroxylation in nitric acid followed by the hydrolysis of the
polynitrofullerenes [65–68]. Preparation of F2 involved 60% of C60Oy(OH)x and 40% of C70Oy(OH)x.
Fullerenes were preliminary synthesized by carbon helium high-frequency arc plasma at atmospheric
pressure [67,69]. The carbon soot included 12.6% of fullerene. The fullerene mixture was extracted
by toluene. Then, the individual fullerene C60 was isolated by liquid chromatography based on
turbostratic graphite with 3.42 Å interplanar distance (as a stationary phase) and a toluene/hexane
mixture (as a mobile phase).
F3 was produced from a powder mixture of fullerene soot and acetylacetonate FeIII (Fe(acac)3).
The mixture was heated up to spontaneous ignition at 180 ◦C. Then, the combustion process proceeded
without additional heating. The product of the combustion reaction was exposed to boiling hydrochloric
acid and the dissolved part of the product was removed. Retreatment with acid was provided to remove
the metal salt. The solid residue of fullerenes was washed with water and used as a precursor in the
synthesis of polyhydroxylated fullerenes (fullerenols). F3 was produced by precursor hydroxylation in
nitric acid followed by the hydrolysis of the polynitrofullerenes [65–68].
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F4 (two molecules of C60-fullerenol are combined by an iron atom) was produced from the powder
which involved Fe-containing C60 fullerene soot and acetylacetonate of FeIII (Fe(acac)3). This mixture
was heated up to spontaneous ignition (180 ◦C); then the temperature increased up to 250 ◦C in the
smoldering regime. The product was treated with concentrated nitric acid (90 ◦C). The red cinnamonic
solution was evaporated and treated by distilled water. The procedure provided the hydrolysis of
poly-nitro-fullerene to poly-hydroxylated fullerene [65,66,68].
F5 (gadolinium atom inside C82-fullerenol) was produced by Gd@C82-fullerene hydroxylation
in nitric acid followed by hydrolysis of the polynitrofullerenes [65,66,68,70]. Mixture of fullerenes,
involving Gd@C82-fullerene, was preliminary synthesized by carbon helium high-frequency arc plasma
at 98 kPa [67,70]. The Gd@C82-fullerene content in carbon soot was about 4.8%. The reaction of
complexation with Lewis acids (TiCl4) was used for enrichment of the extract of fullerene mixture by
endohedral metallofullerenes (Gd@C82) [71]. Then, Gd@C82 was extracted with carbon disulfide from
carbon soot.
The fullerenol preparations were characterized with IR and photoelectron spectroscopies [72,73].
3.2. Bioluminescence Assay Systems and Experimental Data Processing
Antioxidant activity and toxicity of fullerenols were evaluated using bioluminescence assay
systems, both cellular and enzymatic: (1) bacterial assay, i.e., Microbiosensor 677F, was based on
the lyophilized luminous bacteria Photobacterium phosphoreum from the collection of the Institute of
Biophysics SB RAS (CCIBSO 863), strain 667F IBSO, and (2) enzyme preparation was based on the
coupled enzyme system NADH:FMN-oxidoreductase from Vibrio fischeri (0.15 a.u.) and luciferase from
Photobacterium leiognathi, 0.5 mg/mL [74]. All the biological preparations were produced at the Institute
of Biophysics SB RAS (Krasnoyarsk, Russia).
Chemicals used were: NADH from ICN, USA; FMN and tetradecanal from SERVA, Germany;
1,4-benzoquinone from Aldrich, USA; and sodium chloride (NaCl) from Khimreactiv, Russia.
Antioxidant activity of fullerenols was assessed in water solutions of model oxidizer,
1,4-benzoquinone.
To construct the enzymatic assay system, we used 0.1 mg ml−1 enzyme preparation, 4 × 10−4 M
NADH, 5 × 10−4 M FMN, and 0.002% tetradecanal solutions. The enzymatic assay was performed in
0.05 M phosphate buffer, pH 6.8, at 20 ◦C.
The enzymatic assay system is based on two coupled enzymatic reactions:
NADH + FMN NADH:FMN–oxidoreductase−−−−−−−−−−−−−−−−−−−−→ FMN ·H− + NAD− and (reaction 1)
FMN ·H− + RCHO + O2 luci f erase−−−−−−→ FMN + RCOO− + H2O + hv. (reaction 2)
Measurements of bioluminescence intensity were carried out with bioluminometers BLM-3606
(Nauka Special Design Bureau, Russia) and TriStar LB 941 (Berthold Technologies, Germany).
Toxic effects of fullerenols on bioluminescence of bacterial and enzymatic assay systems were
characterized by relative bioluminescence intensity, IrelF :
IrelF = IF/Icontr, (1)
where, Icontr and IF are maximal bioluminescence intensities in the absence and presence of
fullerenols, respectively.
To compare toxic effects of fullerenols, their effective concentrations that inhibited bioluminescence
intensity by 50% (IrelF = 0.5), EC50, were determined.
General toxicity (GT) of the model oxidizer solutions (1,4-benzoquinone) was evaluated with
relative bioluminescence intensity, IrelOx:
IrelOx = IOx/Icontr, (1a)
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where, Icontr and IOx are maximal bioluminescence intensities in the absence and presence of the
oxidizer, respectively, as shown in Figure 7. The effective concentration of model organic oxidizer
(1,4-benzoquinone) that inhibited bioluminescence intensity by 50% (IrelOx = 0.5), EC50, were determined
using bacterial and enzymatic bioluminescence assays. The EC50 values of 1,4-benzoquinone were
2.5 × 10−7 M and 10−4 M for bacterial and enzymatic assays, respectively. The values were close to
those determined in previous studies [49,52].
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Antioxidant activity of fullereno s was evalu ted in mod l solutions of oxidizer (1,4-benzoquinone).
EC50 of the oxidizer was used in these experiments. To exclude the peculiar toxi effec s of the fullerenols,
concentration rang s (CR) of the fullerenols inhibiting the bioluminescence intensity less than 10%
(IrelF > 0.9) were preliminary determined and used in the experiments.
Both bioluminescent assays (bacterial and enzymatic) were applied to study changes in general
toxicity (GT) under the addition of fullerenols. Detoxification coefficients DGT were determined
as follows:
DGT = IrelOx+F/I
rel
Ox, (2)
where IrelOx, I
rel
Ox+F are relative bioluminescence intensities in oxidizer solutions at EC50, in the absence
and presence of fullerenols, respectively, calculated according to Equation (1a). Values of DGT were
determined at different fullerenol concentrations.
To characterize oxidative toxicity (OxT) in the oxidizer solutio s, the bioluminescence enzyme
assay was used. Changes of OxT under fullerenol exposure were characterized with detoxification
coefficients, DOxT:
DOxT = (T0.5)Ox/(T0.5)Ox+F, (3)
where (T0.5)Ox and (T0.5)Ox+F are bioluminescence induction periods in oxidizer solutions in the
absence and presence of fullerenols, respectively (Figure 7b). The DOxT values were determined and
plotted vs. fullerenol concentrations.
Values of DGT > 1 or DOxT > 1 revealed a decrease in GT or OxT under the exposure to fullerenols,
i.e., detoxification of solutions of oxidizers. Values of DGT ≈ 1 or DOxT ≈ 1 revealed an absence of the
fullerenol effect.
The SD values for DGT or DOxT did not exceed 0.1. The data for the DGT or DOxT processing were
obtained in three experiments with five samplings from all control and fullerenol solutions.
It should be noted that all experiments with ’colored’ solutions of fullerenols excluded the effect
of the “optic filter” [29]; this effect did not skew the results the toxicological measurements.
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3.3. Luminol Chemiluminescence Assay
Luminol was obtained from Sigma-Aldrich, potassium hydroxide from Khimreactiv (Russia), and
3% solution of hydrogen peroxide from Tula Pharmaceutical Factory (Russia). The 10−4 M aqueous
alkaline luminol solution was used.
The chemiluminescence luminol reaction was initiated by a solution of K3[Fe(CN)6] and maximal
value of chemiluminescence intensity was determined. All measurements were carried out in 25–40
replicates using TriStar LB 941 bioluminometer with injector system. Average and SD values did not
exceed 0.05.
The dependence of chemiluminescence intensity on H2O2 concentration was initially determined
and it was used as a calibration dependent in the following experiments to evaluate concentrations of
peroxide compounds in the solutions of fullerenols. Peroxides were considered to be components of
the ROS group. The ROS content was plotted vs. concentrations of fullerenols.
To compare the effects of fullerenols on ROS content, their effective concentrations that decreased
chemiluminescence intensity by 50%, EC50, were determined.
4. Conclusions
The current paper analyzed toxicity and antioxidant activity of a series of fullerenols studied
under comparable conditions. In summary, all the fullerenols inhibited bacterial and enzymatic
bioluminescence at high concentrations (>0.01 g L−1, Table 2), producing a toxic effect, while the
antioxidant activity of all the fullerenols was evident at low and ultralow concentrations (<0.001 g L−1,
Table 2). We found that the toxic and antioxidant characteristics of the fullerenols depended, additionally,
on the number of oxygen substituents. Quantitative characteristics of the fullerenols (effective
concentrations, concentration ranges, and detoxification coefficients) were determined and compared.
Lower toxicity and higher antioxidant activity were demonstrated for the fullerenols with fewer
substituents: C60Oy(OH)x and C60,70Oy(OH)x, where x+y = 24–28. The differences were attributed
to fullerenol’ ability to disturb ROS balance in aqueous solutions. Further investigations, including
theoretical studies, should be carried out to understand the physical and chemical basis of these
differences. The investigations should be aimed at such structural fullerenol peculiarities as an
interrelation between the number of oxygen-containing groups and hydrophobic pi-conjugated surface
fragments, with the latter responsible for the reversible electron acceptance and, hence, nonspecific
catalytic activity in chemical and biochemical processes.
As an outlook, a recommendation can be made for the selection and synthesis of fullerene’
water-soluble derivatives: a high number of oxygen substituents (up to 40 and more) provided higher
toxicity and lower antioxidant activity.
Hence, the study demonstrated a suitability and high potential for the bioluminescence-based
biosensing procedure for the complex study of the carbon nanoparticles, which are promising
pharmaceutical agents.
Author Contributions: E.S.K. and A.S.S. were involved in experimental studied using bioluminescence and
chemiluminescence methods, data processing, interpretation, and writing and editing the manuscript. E.M.K.
produced bacterial and enzyme preparations for the experiments. N.G.V. provided qualitative and quantitative
analysis of fullerenes. G.N.C. provided fullerene and fullerenol synthesis. N.S.K. was involved in general leadership
of the work, data analysis, and manuscript preparation. All authors read and approved the final manuscript.
Funding: This work was supported by PRAN-32, Program: ‘Nanostructures: physics, chemistry, biology,
technological basis’; RFBR 18-29-19003; RFBR-Krasnoyarsk Regional Foundation 18-44-240004, Tomsk Polytechnic
University CE Program.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
Int. J. Mol. Sci. 2019, 20, 2324 13 of 16
Abbreviations
CR concentration range
F fullerenol
F1 fullerenol C60Oy(OH)x, where x+y = 24–28
F2 fullerenol C60,70Oy(OH)x, where x+y = 24–28
F3 fullerenol C60,70Oy(OH)x, where x+y = 40–42
F4 fullerenol Fe0,5C60Oy(OH)x, where x+y = 40–42
F5 fullerenol Gd@C82Oy(OH)x, where x+y = 40–42
FMN flavin mononucleotide
GT general toxicity
NADH nicotinamide adenine dinucleotide disodium salt-reduced
OxT oxidative toxicity
ROS reactive oxygen species
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